Momenta Pharmaceuticals, Inc. (MNTA)

[floblu14]

Another rationale for Dew's - Why MNTA -

Based on extensive characterization of the mechanism of action of IVIg, both in animal models and in humans, we rationally designed a series of recombinant drug candidates with the potential to deliver improved therapeutic benefit compared to IVIg. These agents are termed Selective Immunodulators of Fc Receptors (SIF’s), and they selectively modulate the activity of members of the Fcg receptor family. In cell and animal models of immune-complex-mediated autoimmunity, SIF's display up to 500-fold greater potency than IVIg.

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=110893983